Average Co-Inventor Count = 5.51
ph-index = 13
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck Sharp & Dohme Corporation (74 from 2,362 patents)
2. Schering Corporation (47 from 1,829 patents)
3. Pharmacopeia Drug Discovery, Inc. (8 from 52 patents)
4. Pharmacopeia Inc. (5 from 99 patents)
5. Intervet Inc. (2 from 241 patents)
6. Schering-plough Corporation (2 from 28 patents)
7. Intervet International B.v. (1 from 104 patents)
125 patents:
1. 11046714 - 2,2-difluorodioxolo Areceptor antagonists
2. 10954240 - Compounds inhibiting leucine-rich repeat kinase enzyme activity
3. 10822338 - Substituted aminoquinazoline compounds as Aantagonist
4. 10624912 - Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors
5. 10548910 - Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
6. 10544155 - Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
7. 10472347 - Aminopyrazine compounds with A2A antagonist properties
8. 10329289 - 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
9. 10233193 - Fused tricyclic heterocyclic compounds useful for treating HIV infection
10. 10093683 - Factor XIa inhibitors
11. 10011615 - Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties
12. 9868738 - Diazine-fused amidines as BACE inhibitors, compositions, and their use
13. 9861620 - Substituted quinolizine derivatives useful as HIV integrase inhibitors
14. 9809568 - Compounds inhibiting leucine-rich repeat kinase enzyme activity
15. 9688654 - Compounds inhibiting leucine-rich repeat kinase enzyme activity